Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis

F. Chasset; J.-D. Bouaziz; N. Costedoat-Chalumeau; C. Frances; L. Arnaud

doi:10.1111/bjd.15312

journal article May 05, 2017

Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis

F. Chasset J.-D. Bouaziz N. Costedoat-Chalumeau C. Frances L. Arnaud

British Journal of Dermatology Vol. 177 No. 1 pp. 188-196 · Oxford University Press (OUP)

View at Publisher Save 10.1111/bjd.15312

Topics

No keywords indexed for this article. Browse by subject →

References

53

[1]

Cervera "Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus" Medicine (Baltimore) (1993) 10.1097/00005792-199303000-00005

[2]

Merola "Redefining cutaneous lupus erythematosus: a proposed international consensus approach and results of a preliminary questionnaire" Lupus Sci Med (2015) 10.1136/lupus-2015-000085

[3]

Kuhn "The classification and diagnosis of cutaneous lupus erythematosus" J Autoimmun (2014) 10.1016/j.jaut.2014.01.021

[4]

Hejazi "Cutaneous lupus erythematosus: an update on pathogenesis, diagnosis and treatment" Am J Clin Dermatol (2016) 10.1007/s40257-016-0173-9

[5]

Kuhn "Cutaneous lupus erythematosus: update of therapeutic options part I" J Am Acad Dermatol (2011) 10.1016/j.jaad.2010.06.018

[6]

Cavazzana "Treatment of lupus skin involvement with quinacrine and hydroxychloroquine" Lupus (2009) 10.1177/0961203308101714

[7]

Islam "Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus" Int J Rheum Dis (2012) 10.1111/j.1756-185x.2011.01665.x

[8]

Cortés-Hernández "Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome" Br J Dermatol (2012) 10.1111/j.1365-2133.2011.10693.x

[9]

Fennira "Lenalidomide for refractory chronic and subacute cutaneous lupus erythematosus: 16 patients" J Am Acad Dermatol (2016) 10.1016/j.jaad.2016.01.054

[10]

Stang "Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses" Eur J Epidemiol (2010) 10.1007/s10654-010-9491-z

[11]

Higgins (2011)

[12]

Oremus "Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer's disease drug trials" Dement Geriatr Cogn Disord (2001) 10.1159/000051263

[13]

Assessing the quality of reports of randomized clinical trials: Is blinding necessary?

Alejandro R. Jadad, R.Andrew Moore, Dawn Carroll et al.

Controlled Clinical Trials 1996 10.1016/0197-2456(95)00134-4

[14]

Klein "Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus" Arch Dermatol (2011) 10.1001/archdermatol.2010.435

[15]

Barendregt "Meta-analysis of prevalence" J Epidemiol Community Health (2013) 10.1136/jech-2013-203104

[16]

Meta-analysis in clinical trials

Rebecca DerSimonian, Nan Laird

Controlled Clinical Trials 1986 10.1016/0197-2456(86)90046-2

[17]

Kraak "The value of hydroxychloroquine (Plaquenil) for the treatment of chronic discoid lupus erythematosus; a double blind trial" Dermatologica (1965) 10.1159/000254544

[18]

Tuffanelli "Lupus erythematosus panniculitis (profundus)" Arch Dermatol (1971) 10.1001/archderm.1971.04000150001001

[19]

Millard "Chilblain lupus erythematosus (Hutchinson). A clinical and laboratory study of 17 patients" Br J Dermatol (1978) 10.1111/j.1365-2133.1978.tb01935.x

[20]

Callen "Chronic cutaneous lupus erythematosus. Clinical, laboratory, therapeutic, and prognostic examination of 62 patients" Arch Dermatol (1982) 10.1001/archderm.1982.01650180046015

[21]

Spann "Clinical, serologic and immunogenetic studies in patients with chronic cutaneous (discoid) lupus erythematosus who have verrucous and/or hypertrophic skin lesions" J Rheumatol (1988)

[22]

Ruzicka "Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine" Br J Dermatol (1992) 10.1111/j.1365-2133.1992.tb14851.x

[23]

Le Bozec "[Chronic lupus erythematosus in lupus disease. Retrospective study of 136 patients]" Presse Med (1994)

[24]

Rahman "Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus" J Rheumatol (1998)

[25]

Kuhn "Lupus erythematosus tumidus - a neglected subset of cutaneous lupus erythematosus: report of 40 cases" Arch Dermatol (2000) 10.1001/archderm.136.8.1033

[26]

Jewell "Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment" J Am Acad Dermatol (2000) 10.1067/mjd.2000.103635

[27]

Versapuech "[Subacute cutaneous lupus. Evolutive and therapeutic features of a series of 24 cases]" Presse Med (2000)

[28]

Lardet "[Effect of smoking on the effectiveness of antimalarial drugs for cutaneous lesions of patients with lupus: assessment in a prospective study]" Rev Med Interne (2004) 10.1016/s0248-8663(04)00266-8

[29]

Chieregato "Discoid lupus erythematosus: clinical and pathological study of 24 patients" J Eur Acad Dermatol Venereol (2004) 10.1111/j.1468-3083.2004.00849.x

[30]

Choonhakarn "Lupus erythematosus tumidus" Int J Dermatol (2004) 10.1111/j.1365-4632.2004.02073.x

[31]

Bezerra "Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus" Arthritis Rheum (2005) 10.1002/art.21358

[32]

Jacyk "Lupus erythematosus profundus in black South Africans" Int J Dermatol (2006) 10.1111/j.1365-4632.2006.02770.x

[33]

Bouaziz "Cutaneous lesions of the digits in systemic lupus erythematosus: 50 cases" Lupus (2007) 10.1177/0961203306075792

[34]

Kreuter "Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking" Arch Dermatol (2009) 10.1001/archdermatol.2008.592

[35]

Cozzani "Lupus erythematosus tumidus: clinical, histopathological and serological aspects and therapy response of 21 patients" Eur J Dermatol (2010)

[36]

Mahfoudh "[Chronic lupus erythematosus: 104 Tunisian cases]" Tunis Med (2010)

[37]

Wahie "Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study" J Invest Dermatol (2011) 10.1038/jid.2011.167

[38]

Francès "Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study" Arch Dermatol (2012) 10.1001/archdermatol.2011.2558

[39]

Chang "Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis" Arch Dermatol (2011) 10.1001/archdermatol.2011.191

[40]

Piette "Impact of smoking in cutaneous lupus erythematosus" Arch Dermatol (2012) 10.1001/archdermatol.2011.342

[41]

Ikeda "Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study" J Dermatol (2012) 10.1111/j.1346-8138.2011.01448.x

[42]

Yokogawa "Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI)" Mod Rheumatol (2013) 10.3109/s10165-012-0656-3

[43]

Momose "Experience with the use of hydroxychloroquine for the treatment of lupus erythematosus" J Dermatol (2013) 10.1111/1346-8138.12005

[44]

Kuhn "Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database" Br J Dermatol (2014) 10.1111/bjd.13006

[45]

Rodriguez-Caruncho "Lupus erythematosus tumidus: a clinical and histological study of 25 cases" Lupus (2015) 10.1177/0961203314560204

[46]

Yokogawa "A double-blind, randomized, parallel-group study of hydroxychloroquine on cutaneous lupus erythematosus in Japan" Arthritis Rheum (2015)

[47]

Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus

Marc C. Hochberg

Arthritis & Rheumatism 1997 10.1002/art.1780400928

[48]

Feldmann "The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus" Dermatology (1994) 10.1159/000246899

[49]

Lipsker "Chloroquine-quinacrine association in resistant cutaneous lupus" Dermatology (1995) 10.1159/000246710

[50]

Biazar "Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE)" Autoimmun Rev (2013) 10.1016/j.autrev.2012.08.019

Showing 50 of 53 references

Cited By

86

Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus

Victoria P. Werth, Richard A. Furie · 2022

New England Journal of Medicine

Metrics

86

Citations

53

References

Details

Published: May 05, 2017
Vol/Issue: 177(1)
Pages: 188-196
License: View

Authors

F

F. Chasset

AP-HP; Service de Dermatologie et d'Allergologie; Hôpital Tenon; 4 Rue de la Chine Paris CEDEX 20 75970 France

J

J.-D. Bouaziz

AP-HP; Service de Dermatologie; Hôpital Saint Louis; Paris F-75010 France

N

N. Costedoat-Chalumeau

AP-HP; Université René Descartes Paris V; Paris 75005 France; Centre de Référence Maladies Auto-Immunes et Systémiques Rares; Service de Médecine Interne Pôle Médecine; Hôpital Cochin; Paris F-75014 France

C

C. Frances

AP-HP; Service de Dermatologie et d'Allergologie; Hôpital Tenon; 4 Rue de la Chine Paris CEDEX 20 75970 France

L

L. Arnaud

Laboratoire d'ImmunoRhumatologie Moléculaire; Service de Rhumatologie; Hôpitaux Universitaires de Strasbourg; INSERM UMR_S1109; Université de Strasbourg; Strasbourg F-67000 France

Cite This Article

F. Chasset, J.-D. Bouaziz, N. Costedoat-Chalumeau, et al. (2017). Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis. British Journal of Dermatology, 177(1), 188-196. https://doi.org/10.1111/bjd.15312

Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis

You May Also Like